United States - English - NLM (National Library of Medicine)

creekwood pharmaceutical, inc, - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif), estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 1.25 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warning). - undiagnose

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 1.25 milligram - natural and semisynthetic estrogens, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625 mg/2.5 milligram(s) - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625mg/5m percent volume/volume - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 1.25 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 0.625 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - norgestrel, estrogens conjugated - coated tablet - norgestrel 0.15 mg estrogens conjugated 0.625 mg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - norgestrel, estrogens conjugated - coated tablet - norgestrel 0.15 mg estrogens conjugated 1.25 mg - sex hormones and modulators of the genital system

Canada - English - Health Canada

pfizer canada ulc - conjugated estrogens; bazedoxifene (bazedoxifene acetate) - tablet (immediate and extended release) - 0.45mg; 20mg - conjugated estrogens 0.45mg; bazedoxifene (bazedoxifene acetate) 20mg - estrogen agonist-antagonists